Literature DB >> 21289245

1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells.

Sunil K Halder1, J Shawn Goodwin, Ayman Al-Hendy.   

Abstract

BACKGROUND: Uterine leiomyomas (fibroids) are the most common benign estrogen-dependent tumors of premenopausal women. TGF-β3 up-regulates the synthesis of many of extracellular matrix proteins that are associated with tissue fibrosis.
OBJECTIVE: To examine the effect of 1,25-dihydroxyvitamin D(3) (vitamin D(3)) on TGF-β3-induced fibrosis-related protein expression in immortalized human uterine leiomyoma (HuLM) cells.
METHODS: HuLM cells were treated with TGF-β3 with or without vitamin D(3). Western blot analyses were employed to test the effect of vitamin D(3) on TGF-β3-induced protein expression of collagen type 1, fibronectin, and plasminogen activator inhibitor-1 proteins. Western blots as well as immunofluorescence analyses were used to verify the effect of vitamin D(3) on TGF-β3-induced Smad activation involved in extracellular matrix protein synthesis and deposition, which ultimately lead to tissue fibrosis.
RESULTS: We observed that TGF-β3 induced fibronectin and collagen type 1 protein expression in HuLM cells, and that effect was suppressed by vitamin D(3). TGF-β3 also induced protein expression of plasminogen activator inhibitor-1, an important TGF-β target, in HuLM cells, which was also inhibited by vitamin D(3). Additionally, TGF-β3 induced phosphorylation of Smad2 as well as nuclear translocation of Smad2 and Smad3 in HuLM cells, whereas vitamin D significantly reduced all these TGF-β3-mediated effects. Therefore, our results suggest that vitamin D(3) has consistently reduced TGF-β3 effects that are involved in the process of fibrosis in human leiomyoma cells.
CONCLUSION: Vitamin D(3) is an antifibrotic factor that might be potentially useful as a novel therapeutic for nonsurgical treatment of benign uterine fibroids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289245      PMCID: PMC3070259          DOI: 10.1210/jc.2010-2131

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays.

Authors:  Minnie Malik; William H Catherino
Journal:  Fertil Steril       Date:  2007-01-12       Impact factor: 7.329

2.  Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro.

Authors:  S J Chen; C M Artlett; S A Jimenez; J Varga
Journal:  Gene       Date:  1998-07-17       Impact factor: 3.688

Review 3.  TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties.

Authors:  J Massagué; S Cheifetz; F T Boyd; J L Andres
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 4.  Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation.

Authors:  Franck Verrecchia; Alain Mauviel
Journal:  J Invest Dermatol       Date:  2002-02       Impact factor: 8.551

5.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

6.  Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation.

Authors:  A Arici; I Sozen
Journal:  Fertil Steril       Date:  2000-05       Impact factor: 7.329

Review 7.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

Review 8.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

9.  Hysterectomy in the United States, 1988-1990.

Authors:  L S Wilcox; L M Koonin; R Pokras; L T Strauss; Z Xia; H B Peterson
Journal:  Obstet Gynecol       Date:  1994-04       Impact factor: 7.661

10.  Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle.

Authors:  E A Stewart; A J Friedman; K Peck; R A Nowak
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  66 in total

1.  1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.

Authors:  Sunil K Halder; Chakradhari Sharan; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2012-04-19       Impact factor: 4.285

Review 2.  Vitamin D: Implications for ocular disease and therapeutic potential.

Authors:  Rose Y Reins; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-02-25       Impact factor: 3.467

Review 3.  Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy.

Authors:  Mostafa A Borahay; Ayman Al-Hendy; Gokhan S Kilic; Darren Boehning
Journal:  Mol Med       Date:  2015-04-13       Impact factor: 6.354

4.  1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells.

Authors:  Sunil K Halder; Kevin G Osteen; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2013-12-26       Impact factor: 4.285

5.  Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.

Authors:  James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon
Journal:  Hum Reprod Update       Date:  2014-01-08       Impact factor: 15.610

6.  Can vitamin D reduce the risk of uterine fibroids?

Authors:  Ayman Al-Hendy; Marwa Badr
Journal:  Womens Health (Lond)       Date:  2014-07

7.  Matrix production and remodeling as therapeutic targets for uterine leiomyoma.

Authors:  Caitlin Fujisawa; John J Castellot
Journal:  J Cell Commun Signal       Date:  2014-07-11       Impact factor: 5.782

8.  Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study.

Authors:  Erica E Marsh; Geraldine E Ekpo; Eden R Cardozo; Maureen Brocks; Tanaka Dune; Leeber S Cohen
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

9.  Vitamin d and the risk of uterine fibroids.

Authors:  Donna Day Baird; Michael C Hill; Joel M Schectman; Bruce W Hollis
Journal:  Epidemiology       Date:  2013-05       Impact factor: 4.822

Review 10.  Epidemiology of Uterine Fibroids: From Menarche to Menopause.

Authors:  Lauren A Wise; Shannon K Laughlin-Tommaso
Journal:  Clin Obstet Gynecol       Date:  2016-03       Impact factor: 2.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.